Business Pipeline How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup BioPharma DiveCohen says he looked at around two dozen companies since Acorda wound down.PipelineNeuroscienceRead full story pharminent March 24, 2026 (Last updated: March 24, 2026) BioPharma Dive Cohen says he looked at around two dozen companies since Acorda wound down. PipelineNeuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study resultsNext: NOW AVAILABLE: The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers Related Stories Pipeline New biotech cAMPfield emerges with $180M to reshape IBD treatment pharminent June 18, 2026 Pipeline J&J adds rare disease wAIHA to Imaavy’s potential uses pharminent June 11, 2026 Pipeline Novartis gets win for another Avidity muscular dystrophy AOC pharminent June 11, 2026
